Bevacizumab therapy for recurrent gliomas: another disappointment?

Affiliations

¹ Department of Neurosurgery, Klinikum rechts der Isar, Technical University Munich, 81675 Munich, Germany.
² Department of Neurosurgery, Klinikum rechts der Isar, Technical University Munich, 81675 Munich, Germany. Electronic address: bernhard.meyer@tum.de.

Comment

Jens Gempt et al. Lancet Oncol. 2018 Sep.

. 2018 Sep;19(9):1137-1138.

doi: 10.1016/S1470-2045(18)30601-6. Epub 2018 Aug 13.

¹ Department of Neurosurgery, Klinikum rechts der Isar, Technical University Munich, 81675 Munich, Germany.
² Department of Neurosurgery, Klinikum rechts der Isar, Technical University Munich, 81675 Munich, Germany. Electronic address: bernhard.meyer@tum.de.

No abstract available

Comment on

Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial.
van den Bent MJ, Klein M, Smits M, Reijneveld JC, French PJ, Clement P, de Vos FYF, Wick A, Mulholland PJ, Taphoorn MJB, Lewis J, Weller M, Chinot OL, Kros JM, de Heer I, Verschuere T, Coens C, Golfinopoulos V, Gorlia T, Idbaih A. van den Bent MJ, et al. Lancet Oncol. 2018 Sep;19(9):1170-1179. doi: 10.1016/S1470-2045(18)30362-0. Epub 2018 Aug 13. Lancet Oncol. 2018. PMID: 30115593 Clinical Trial.